 |
|
|
| |
Switching to Doravirine/Islatravir (100 mg/0.25 mg) Once Daily Maintained Viral Suppression at Week 96 in the Presence of Baseline NNRTI Resistance-Associated Mutations and/or M184I/V in Proviral DNA
|
| |
| |
IAS 2026 Rio, Brazil
Tracy L. Diamond, Uchechukwu Nwoke, Monica Fuszard, Chenguang Zhang, Stephanie O. Klopfer, Mengchun Li, Wayne Greaves, Jason Kim, Michelle C. Fox, Ernest Asante-Appiah
Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA
|
| |
|
|
|
|
|
